A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no cure. Engineering better ...

HIV’s Tat protein blocks autophagy in macrophages, letting Mtb thrive. This may explain why HIV patients face higher TB risk even on ART.

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...

The patient, who had a history of undetectable HIV-1 RNA levels since 1997 while receiving antiretroviral therapy, had remission from AML after salvage chemotherapy (Table S2). HCT was recommended for ...

Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor designed to inhibit HIV replication at multiple stages of its lifecycle. The Food and Drug Administration (FDA) has approved ...

A 53-year-old from Düsseldorf in Germany has become the third person in the world to be completely cured of HIV following a stem cell transplant using donor cells with a particular genetic mutation.

In a recent study posted to Research Square* preprint server, researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV envelope (E) proteins on ...